Showing results (7301-7310 of 10,083) with videos related to
Sort By:
Pageof 1,009
Current Pharmaceutical Design|July 6, 2012
Recent advances in preoperative cardiac evaluationHans-Joachim PriebeCurrent Pharmaceutical Design|June 16, 2012
A computational study of the oligosaccharide binding sites in the lectin-like domain of Tumor Necrosis Factor and the TNF-derived TIP peptideAlexander Dulebo, Rudiger Ettrich, Rudolf Lucas, et al.Current Pharmaceutical Design|June 22, 2012
The yin and yang of cannabis-induced psychosis: the actions of Δ(9)-tetrahydrocannabinol and cannabidiol in rodent models of schizophreniaJ C Arnold, A A Boucher, T KarlCurrent Pharmaceutical Design|June 22, 2012
Cannabis in the arm: what can we learn from intravenous cannabinoid studies?Amir Englund, James M Stone, Paul D MorrisonCurrent Pharmaceutical Design|June 22, 2012
Antipsychotic-like effects of cannabidiol and rimonabant: systematic review of animal and human studiesPatrik Roser, Ida S HaussleiterCurrent Pharmaceutical Design|June 22, 2012
Cannabis use in patients at clinical high risk of psychosis: impact on prodromal symptoms and transition to psychosisFloor J van der Meer, Eva Velthorst, Carin J Meijer, et al.Current Pharmaceutical Design|June 22, 2012
The endocannabinoid system and schizophrenia: integration of evidenceErica Zamberletti, Tiziana Rubino, Daniela ParolaroCurrent Pharmaceutical Design|January 30, 2010
Circumventing immune tolerance through epigenetic modificationJason A Dubovsky, Alejandro Villagra, John J Powers, et al.Current Pharmaceutical Design|January 30, 2010
Metabolic immune restraints: implications for anticancer vaccinesSimone MocellinCurrent Pharmaceutical Design|January 30, 2010
Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: from animal models to human pathophysiologyMorten S Thomsen, Henrik H Hansen, Daniel B Timmerman, et al.Pageof 1,009